期刊文献+

HER-2阳性乳腺癌中肿瘤浸润淋巴细胞与雄激素受体的相关性研究 被引量:6

Correlation between tumor-infiltrating lymphocytes and the androgen receptor in HER-2-positive breast cancer
下载PDF
导出
摘要 目的:探讨人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)阳性乳腺癌中肿瘤浸润淋巴细胞(tumor-infiltrating lymphocytes,TILs)浸润水平与雄激素受体(androgen receptor,AR)表达的关系。方法:收集2018年3月至2018年11月天津医科大学肿瘤医院收治的448例HER-2阳性乳腺癌患者的临床资料。病理评估TILs浸润水平,免疫组织化学方法检测AR表达情况,分析TILs浸润水平和AR表达与临床病理学参数的关系以及TILs和AR的相关性。结果:448例HER-2阳性乳腺癌患者中TILs无浸润或低浸润的患者占38.2%(171/448)、中等浸润者占42.2%(189/448)、高浸润者占19.6%(88/448),AR阳性率为62.7%(281/448)。Spearman等级相关分析显示TILs浸润水平与AR表达呈负相关(r=-0.140,P=0.003)。在雌激素受体(estrogenreceptor,ER)阳性乳腺癌中,TILs浸润水平和AR表达密切相关(P=0.009)。结论:HER-2阳性乳腺中TILs浸润水平和AR表达呈负相关,提示HER-2阳性乳腺癌患者可根据TILs的不同浸润水平与AR的表达行精准治疗。 Objective: To investigate the relationship between tumor-infiltrating lymphocytes (TILs) and the androgen receptor (AR) in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer. Methods: Specimens of 448 patients with HER-2-positive breast cancer from the Tianjin Medical University Cancer Hospital between March 2018 and November 2018 were collected. TILs were pathologically evaluated. AR expression was immunohistochemically analyzed. The relationships among TILs, the AR, and clinicopathological parameters were determined. Results: There were 38.2%(171/448) patients with TILs non/low-infiltrated, 42.2%(189/448) with moderately infiltrated, and 19.6%(88/448) with high infiltration. AR was positive in 62.7%(281/448) of the patients. Spearman correlation analysis showed that TILs and the AR were negatively related (r=-0.140, P=0.003). TILs were significantly associated with the AR in estrogen receptor positive breast cancer (P=0.009). Conclusions: TILs and the AR were negatively related in HER-2-positive breast cancer, indicating that HER-2-positive breast cancer can be treated according to the different infiltration levels of TILs and AR expression.
作者 刘方 曹璐 许聪 向国敏 牛昀 Fang Liu;Lu Cao;Cong Xu;Guomin Xiang;Yun Niu(Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin 300060, China)
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2019年第8期389-393,共5页 Chinese Journal of Clinical Oncology
基金 天津市应用基础与前沿技术研究计划基金项目(编号:15JCYBJC27800)资助~~
关键词 乳腺癌 人表皮生长因子受体-2 肿瘤浸润淋巴细胞 雄激素受体 breast cancer human epidermal growth factor receptor 2 (HER-2) tumor-infiltrating lymphocytes androgen receptor
  • 相关文献

同被引文献73

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部